US › Healthcare

Entrada Therapeutics Inc (TRDA)

US · Healthcare · Biotechnology

$7.24-0.28%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$875,000
Revenue YoY
-95.7%
Net profit
$-39.7M
Profit YoY
-128.9%
EPS
$-0.95
EPS estimate
$-1.02
Net margin
-4,539.1%

EPS came in at -0.95 against a street estimate of -1.02 — a beat of 6.9%.

Key statistics

Market cap
$254.3M
Forward P/E
3,333.3
P/B
0.94
Book value
$7.52
EPS (TTM)
$-4.00
52-week high
$16.45
52-week low
$4.93
50-day MA
$6.74
200-day MA
$9.63
Beta
-0.26

Analyst view

Analysts rate Entrada Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $18.75.

Shareholding

Insiders
12.31%
Institutions
78.94%

Largest institutional holders

FundStake
Baker Bros Advisors LP13.07%
5AM Venture Management, LLC10.45%
BlackRock Inc6.08%
TCG Crossover Management, LLC5.89%
Vanguard Group Inc4.21%
Vanguard Capital Management, LLC3.24%
Wellington Management Company LLP2.67%
StepStone Group LLC1.96%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Entrada Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.